1.2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Jong Han CHOI ; Kyung Ae LEE ; Joon Ho MOON ; Suk CHON ; Dae Jung KIM ; Hyun Jin KIM ; Nan Hee KIM ; Ji A SEO ; Mee Kyoung KIM ; Jeong Hyun LIM ; YoonJu SONG ; Ye Seul YANG ; Jae Hyeon KIM ; You-Bin LEE ; Junghyun NOH ; Kyu Yeon HUR ; Jong Suk PARK ; Sang Youl RHEE ; Hae Jin KIM ; Hyun Min KIM ; Jung Hae KO ; Nam Hoon KIM ; Chong Hwa KIM ; Jeeyun AHN ; Tae Jung OH ; Soo-Kyung KIM ; Jaehyun KIM ; Eugene HAN ; Sang-Man JIN ; Won Suk CHOI ; Min Kyong MOON ; ;
Diabetes & Metabolism Journal 2023;47(5):575-594
In May 2023, the Committee of Clinical Practice Guidelines of the Korean Diabetes Association published the revised clinical practice guidelines for Korean adults with diabetes and prediabetes. We incorporated the latest clinical research findings through a comprehensive systematic literature review and applied them in a manner suitable for the Korean population. These guidelines are designed for all healthcare providers nationwide, including physicians, diabetes experts, and certified diabetes educators who manage patients with diabetes or individuals at risk of developing diabetes. Based on recent changes in international guidelines and the results of a Korean epidemiological study, the recommended age for diabetes screening has been lowered. In collaboration with the relevant Korean medical societies, recently revised guidelines for managing hypertension and dyslipidemia in patients with diabetes have been incorporated into this guideline. An abridgment containing practical information on patient education and systematic management in the clinic was published separately.
2.Incidence, Morbidity, and Mortality of Achalasia: A Nationwide, Population-Based Cohort Study in South Korea
Ga Hee KIM ; Hyungchul PARK ; Kee Wook JUNG ; Min-Ju KIM ; Ye-Jee KIM ; Ji Min LEE ; Bong Eun LEE ; Yang Won MIN ; Jeong Hwan KIM ; Hee Kyong NA ; Ji Yong AHN ; Jeong Hoon LEE ; Do Hoon KIM ; Kee Don CHOI ; Ho June SONG ; Gin Hyug LEE ; Hwoon-Yong JUNG ; Hyun Jin KIM ;
Gut and Liver 2023;17(6):894-904
Background/Aims:
Although an association between achalasia and esophageal cancer has been reported, whether achalasia confers a substantial increase in mortality is unknown. Moreover, the causes of death related to achalasia have not been investigated. We performed this nationwide, population-based cohort study on achalasia because no such study has been performed since the introduction of high-resolution manometry in 2008.
Methods:
This study was performed using data extracted from the Korean National Health Insurance Service database, covering a 9-year period from 2009 to 2017. Control participants without a diagnostic code for achalasia were randomly selected and matched by sex and birth year at a case-to-control ratio of 1:4. Data on the cause of death from Statistics Korea were also analyzed.
Results:
The overall incidence of achalasia was 0.68 per 100,000 person-years, and the prevalence was 6.46 per 100,000 population. Patients with achalasia (n=3,063) had significantly higher adjusted hazard ratio (aHR) for esophageal cancer (aHR, 3.40; 95% confidence interval [CI], 1.25 to 9.22; p=0.017), pneumonia (aHR, 2.30; 95% CI, 1.89 to 2.81; p<0.001), aspiration pneumonia (aHR, 3.92; 95% CI, 2.38 to 6.48; p<0.001), and mortality (aHR, 1.68; 95% CI, 1.44 to 1.94; p<0.001). Esophageal cancer carried the highest mortality risk (aHR, 8.82; 95% CI, 2.35 to 33.16; p=0.001), while pneumonia had the highest non-cancer mortality risk (aHR, 2.28; 95% CI, 1.31 to 3.96; p=0.004).
Conclusions
In this nationwide study, achalasia was associated with increased risk of mortality.Esophageal cancer and pneumonia were the most common comorbidities and the major causes of death in patients with achalasia.
3.Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19
Jin Yeong HONG ; Jae-Hoon KO ; Jinyoung YANG ; Soyoung HA ; Eliel NHAM ; Kyungmin HUH ; Sun Young CHO ; Cheol-In KANG ; Doo Ryeon CHUNG ; Jin Yang BAEK ; You Min SOHN ; Hyo Jung PARK ; Beomki LEE ; Hee Jae HUH ; Eun-Suk KANG ; Gee Young SUH ; Chi Ryang CHUNG ; Kyong Ran PECK
Yonsei Medical Journal 2022;63(5):430-439
Purpose:
Real-world experience with tocilizumab in combination with dexamethasone in patients with severe coronavirus disease (COVID-19) needs to be investigated.
Materials and Methods:
A retrospective cohort study was conducted to evaluate the effect of severity-adjusted dosing of dexamethasone in combination with tocilizumab for severe COVID-19 from August 2020 to August 2021. The primary endpoint was 30-day clinical recovery, which was defined as no oxygen requirement or referral after recovery.
Results:
A total of 66 patients were evaluated, including 33 patients in the dexamethasone (Dexa) group and 33 patients in the dexamethasone plus tocilizumab (DexaToci) group. The DexaToci group showed a statistically significant benefit in 30-day clinical recovery, compared to the Dexa group (p=0.024). In multivariable analyses, peak FiO2 within 3 days and tocilizumab combination were consistently significant for 30-day recovery (all p<0.05). The DexaToci group showed a significantly steeper decrease in FiO2 (-4.2±2.6) than the Dexa group (−2.7±2.6; p=0.021) by hospital day 15. The duration of oxygen requirement was significantly shorter in the DexaToci group than the Dexa group (median, 10.0 days vs. 17.0 days; p=0.006). Infectious complications and cellular and humoral immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the convalescence stage were not different between the two groups.
Conclusion
A combination of severity-adjusted dexamethasone and tocilizumab for the treatment of severe COVID-19 improved clinical recovery without increasing infectious complications or hindering the immune response against SARS-CoV-2.
4.Multi-Center Study on Gender Difference in Resectability and Pathologic Prognosis of Gallbladder Cancer
Yang Tae PARK ; Jinhyong KANG ; Jae Seon KIM ; Min Kyu JUNG ; Seong Hun KIM ; Jae Hee CHO ; Sang Myung WOO ; Kyong Joo LEE ; Eui Joo KIM ; Hyo Jung KIM
Korean Journal of Pancreas and Biliary Tract 2022;27(3):121-127
Background:
/Aim: In gallbladder cancer (GBC), gender differences in incidence and mortality rates have been reported with geographic variation. However, there is little known about sex-related difference in GBC prognosis. This study compares prognostic factors according to gender for GBC.
Methods:
We searched clinicopathological factors in all stages of 952 GBC patients from seven medical centers in Korea. A total of 927 patients were enrolled and surgery with curative resection was performed in 499 patients.
Results:
Carbohydrate antigen (≥37 U/mL) was a significant prognostic factor in both females and males (odd ratio [OR], 4.30; 95% confidence interval [CI], 3.13-5.89; p<0.001). Age was a significant factor only in female patients, elderly patients were associated with low resectability and the likelihood of T-stage >2; an independent predictor of poor prognosis via multivariate analysis (OR, 1.03; 95% CI, 1.01-1.05; p=0.005, OR, 1.05; 95% CI, 1.02-1.08; p=0.002). Body mass index (BMI) also showed gender difference, and lower BMI (≤25 kg/m2) was the significant good indicator of multivariate analysis for lymph node metastasis in female patients (OR, 0.42; 95% CI, 0.23-0.77; p=0.005) but, the significant poor indicator of univariate analysis for advanced T-stage in male (OR, 2.79; 95% CI, 1.40-5.54; p=0.003).
Conclusions
These results suggest that there is a possibility of gender difference in GBC prognosis. Age and high BMI were poor prognostic factors for curative resection for female GBC patients.
5.Multidisciplinary and Multisociety Practice Guideline on Reprocessing Flexible Gastrointestinal Endoscopes and Endoscopic Accessories
Dae Young CHEUNG ; Byung Ik JANG ; Sang Wook KIM ; Jie-Hyun KIM ; Hyung Keun KIM ; Jeong Eun SHIN ; Won Jae YOON ; Yong Kang LEE ; Kwang Hyun CHUNG ; Soo-Jeong CHO ; Hyun Phil SHIN ; Sun Young CHO ; Woon Geon SHIN ; Kee Don CHOI ; Byung-Wook KIM ; Joong Goo KWON ; Hee Chan YANG ; Tae-Geun GWEON ; Hyun Gun KIM ; Dong-Won AHN ; Kwang Bum CHO ; Sun Hee KIM ; Kyong Hwa HWANG ; Hee Hyuk IM
Clinical Endoscopy 2020;53(3):276-285
The area of endoscopic application has been continuously expanded since its introduction in the last century and the frequency of its use also increased stiffly in the last decades. Because gastrointestinal endoscopy is naturally exposed to diseased internal organs and contact with pathogenic materials, endoscopy mediated infection or disease transmission becomes a major concern in this field. Gastrointestinal endoscopy is not for single use and the proper reprocessing process is a critical factor for safe and reliable endoscopy procedures. What needed in these circumstances is a practical guideline for reprocessing the endoscope and its accessories which is feasible in the real clinical field to guarantee acceptable prevention of pathogen transmission. This guideline contains principles and instructions of the reprocessing procedure according to the step by step. And it newly includes general information and updated knowledge about endoscopy-mediated infection and disinfection. Multiple societies and working groups participated to revise; Korean Association for the Study of the Liver, the Korean Society of Infectious Diseases, Korean College of Helicobacter and Upper Gastrointestinal Research, the Korean Society of Gastroenterology, Korean Society of Gastrointestinal Cancer, Korean Association for the Study of Intestinal Diseases, Korean Pancreatobiliary Association, the Korean Society of Gastrointestinal Endoscopy Nurses and Associates and Korean Society of Gastrointestinal Endoscopy. Through this cooperation, we enhanced communication and established a better concordance. We still need more researches in this field and fill up the unproven area. And our guidelines will be renewed accordingly.
6.RNA-Seq De Novo Assembly and Differential Transcriptome Analysis of Korean Medicinal Herb Cirsium japonicum var. spinossimum
Neha Samir ROY ; Jung A KIM ; Ah Young CHOI ; Yong Wook BAN ; Nam Il PARK ; Kyong Cheul PARK ; Hee sun YANG ; Ik Young CHOI ; Soonok KIM
Genomics & Informatics 2018;16(4):e34-
Cirsium japonicum belongs to the Asteraceae or Compositae family and is a medicinal plant in Asia that has a variety of effects, including tumour inhibition, improved immunity with flavones, and antidiabetic and hepatoprotective effects. Silymarin is synthesized by 4-coumaroyl-CoA via both the flavonoid and phenylpropanoid pathways to produce the immediate precursors taxifolin and coniferyl alcohol. Then, the oxidative radicalization of taxifolin and coniferyl alcohol produces silymarin. We identified the expression of genes related to the synthesis of silymarin in C. japonicum in three different tissues, namely, flowers, leaves, and roots, through RNA sequencing. We obtained 51,133 unigenes from transcriptome sequencing by de novo assembly using Trinity v2.1.1, TransDecoder v2.0.1, and CD-HIT v4.6 software. The differentially expressed gene analysis revealed that the expression of genes related to the flavonoid pathway was higher in the flowers, whereas the phenylpropanoid pathway was more highly expressed in the roots. In this study, we established a global transcriptome dataset for C. japonicum. The data shall not only be useful to focus more deeply on the genes related to product medicinal metabolite including flavolignan but also to study the functional genomics for genetic engineering of C. japonicum.
Asia
;
Asteraceae
;
Cirsium
;
Dataset
;
Estrone
;
Flavones
;
Flowers
;
Gene Expression Profiling
;
Genetic Engineering
;
Genomics
;
Humans
;
Plants, Medicinal
;
Sequence Analysis, RNA
;
Silymarin
;
Transcriptome
7.Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea.
Won Suk CHOI ; Cheol In KANG ; Yonjae KIM ; Jae Phil CHOI ; Joon Sung JOH ; Hyoung Shik SHIN ; Gayeon KIM ; Kyong Ran PECK ; Doo Ryeon CHUNG ; Hye Ok KIM ; Sook Hee SONG ; Yang Ree KIM ; Kyung Mok SOHN ; Younghee JUNG ; Ji Hwan BANG ; Nam Joong KIM ; Kkot Sil LEE ; Hye Won JEONG ; Ji Young RHEE ; Eu Suk KIM ; Heungjeong WOO ; Won Sup OH ; Kyungmin HUH ; Young Hyun LEE ; Joon Young SONG ; Jacob LEE ; Chang Seop LEE ; Baek Nam KIM ; Young Hwa CHOI ; Su Jin JEONG ; Jin Soo LEE ; Ji Hyun YOON ; Yu Mi WI ; Mi Kyong JOUNG ; Seong Yeon PARK ; Sun Hee LEE ; Sook In JUNG ; Shin Woo KIM ; Jae Hoon LEE ; Hyuck LEE ; Hyun Kyun KI ; Yeon Sook KIM
Infection and Chemotherapy 2016;48(2):118-126
BACKGROUND: From May to July 2015, the Republic of Korea experienced the largest outbreak of Middle East respiratory syndrome (MERS) outside the Arabian Peninsula. A total of 186 patients, including 36 deaths, had been diagnosed with MERS-coronavirus (MERS-CoV) infection as of September 30th, 2015. MATERIALS AND METHODS: We obtained information of patients who were confirmed to have MERS-CoV infection. MERS-CoV infection was diagnosed using real-time reverse-transcriptase polymerase chain reaction assay. RESULTS: The median age of the patients was 55 years (range, 16 to 86). A total of 55.4% of the patients had one or more coexisting medical conditions. The most common symptom was fever (95.2%). At admission, leukopenia (42.6%), thrombocytopenia (46.6%), and elevation of aspartate aminotransferase (42.7%) were observed. Pneumonia was detected in 68.3% of patients at admission and developed in 80.8% during the disease course. Antiviral agents were used for 74.7% of patients. Mechanical ventilation, extracorporeal membrane oxygenation, and convalescent serum were employed for 24.5%, 7.1%, and 3.8% of patients, respectively. Older age, presence of coexisting medical conditions including diabetes or chronic lung disease, presence of dyspnea, hypotension, and leukocytosis at admission, and the use of mechanical ventilation were revealed to be independent predictors of death. CONCLUSION: The clinical features of MERS-CoV infection in the Republic of Korea were similar to those of previous outbreaks in the Middle East. However, the overall mortality rate (20.4%) was lower than that in previous reports. Enhanced surveillance and active management of patients during the outbreak may have resulted in improved outcomes.
Antiviral Agents
;
Aspartate Aminotransferases
;
Coronavirus Infections*
;
Disease Outbreaks
;
Dyspnea
;
Extracorporeal Membrane Oxygenation
;
Fever
;
Humans
;
Hypotension
;
Leukocytosis
;
Leukopenia
;
Lung Diseases
;
Middle East Respiratory Syndrome Coronavirus
;
Middle East*
;
Mortality
;
Pneumonia
;
Polymerase Chain Reaction
;
Republic of Korea*
;
Respiration, Artificial
;
Thrombocytopenia
8.A Case of Eosinophilic Granulomatosis with Polyangiitis Presenting with Subarachnoid Hemorrhage and Mononeuritis Multiplex.
Se Hwan OH ; Won PARK ; Seong Ryul KWON ; Mie Jin LIM ; Ko Woon JOO ; Oh Hyun LEE ; Ha Young LEE ; Se Yang OH ; Kyong Hee JUNG
Journal of Rheumatic Diseases 2015;22(3):190-194
Eosinophilic granulomatosis with polyangiitis (EGPA), previously called Churg-Strauss syndrome, is an anti-neutrophil cytoplasmic antibody associated vasculitis, accompanied by asthma, hypereosinophilia, nonfixed pulmonary infiltrates, and sinusitis. Peripheral neuropathy is common in patients with EGPA; however, a few cases of EGPA with central nervous system (CNS) involvement have been reported. A 45-year-old female referred for right side weakness and posterior neck pain was diagnosed as EGPA with subarachnoid hemorrhage and mononeuritis multiplex. She was effectively treated with a high dose glucocorticoid, cyclophosphamide, and intravenous immunoglobulin. EGPA with CNS involvement is uncommon and causes significant morbidity and mortality. Therefore more rapid and accurate diagnostic evaluation may be required. EGPA should be considered in patients with neurological symptoms and hypereosinophilia.
Antibodies, Antineutrophil Cytoplasmic
;
Asthma
;
Central Nervous System
;
Churg-Strauss Syndrome
;
Cyclophosphamide
;
Eosinophils*
;
Female
;
Humans
;
Immunoglobulins
;
Middle Aged
;
Mononeuropathies*
;
Mortality
;
Neck Pain
;
Peripheral Nervous System Diseases
;
Sinusitis
;
Subarachnoid Hemorrhage*
;
Vasculitis
9.Prevention of Venous Thromboembolism, 2nd Edition: Korean Society of Thrombosis and Hemostasis Evidence-Based Clinical Practice Guidelines.
Soo Mee BANG ; Moon Ju JANG ; Kyoung Ha KIM ; Ho Young YHIM ; Yeo Kyeoung KIM ; Seung Hyun NAM ; Hun Gyu HWANG ; Sung Hwa BAE ; Sung Hyun KIM ; Yeung Chul MUN ; Yang Ki KIM ; Inho KIM ; Won Il CHOI ; Chul Won JUNG ; Nan Hee PARK ; Nam Kyong CHOI ; Byung Joo PARK ; Doyeun OH
Journal of Korean Medical Science 2014;29(2):164-171
In 2010, we proposed the first Korean Guidelines for the Prevention of Venous Thromboembolism (VTE). It was applicable to Korean patients, by modifying the contents of the second edition of the Japanese guidelines for the prevention of VTE and the 8th edition of the American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines. From 2007 to 2011, we conducted a nationwide study regarding the incidence of VTE after major surgery using the Health Insurance Review and Assessment Service (HIRA) database. In addition, we have considered the 9th edition of the ACCP Evidenced-Based Clinical Practice Guidelines, published in 2012. It emphasized the importance of clinically relevant events as opposed to asymptomatic outcomes with preferences for both thrombotic and bleeding outcomes. Thus, in the development of the new Korean guidelines, three major points were addressed: 1) the new guidelines stratify patients into 4 risk groups (very low, low, moderate, and high) according to the actual incidence of symptomatic VTE from the HIRA databases; 2) the recommended optimal VTE prophylaxis for each group was modified according to condition-specific thrombotic and bleeding risks; 3) guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and/or physician advice.
Age Factors
;
Anticoagulants/adverse effects/*therapeutic use
;
Asian Continental Ancestry Group
;
Evidence-Based Medicine
;
Heparin, Low-Molecular-Weight/therapeutic use
;
Humans
;
*Mechanical Thrombolysis
;
Neoplasms/complications/surgery
;
Republic of Korea
;
Risk Assessment
;
Surgical Procedures, Operative/adverse effects
;
Venous Thromboembolism/etiology/prevention & control/*therapy
10.Clinical evaluation of the bleaching effect of chewing gum containing amorphous calcium phosphate, hydroxyapatite, and tricalcium pyrophosphate on human enamel.
Eun Kyong KIM ; Ho Young YOON ; Hae Young YANG ; Min Jeong CHO ; Youn Hee CHOI ; Keun Bae SONG
Journal of Korean Academy of Oral Health 2013;37(3):126-131
OBJECTIVES: The purpose of this study was to evaluate the bleaching effect of chewing gum containing amorphous calcium phosphate (ACP), hydroxyapatite (HA), and tricalcium pyrophosphate (TSP) on human enamel. METHODS: Seventy-three subjects aged 20-30 years were recruited after obtaining their informed consent and approval of the Institutional Review Board. All subjects were randomly assigned to the following four groups: (I) negative control group; (II) 50% gum group; (III) 100% gum group; and (IV) positive control group (10% carbamide peroxide). They received gum containing ACP, HA, and TSP, three times a day, for 4 weeks. Group IV also received 10% CP application using individual trays, once a day, for 2 weeks. Color change was measured using the Shade Eye-NCC colorimeter at weekly intervals, during the 4-week period. Statistical analysis was performed using SPSS 18.0. RESULTS: Color changes (DeltaE*) were significantly different among the groups at 2 and 4 weeks after chewing the gum (P<0.05). Given that bleaching effect of Group IV was 100%, bleaching effects of Group III, Group II, and Group I were 54%, 46%, and 36%, respectively. CONCLUSIONS: Chewing gum containing ACP, HA, and TSP was effective enough to bleach the human enamel. Further comprehensive studies and assessment will be required to ascertain the bleaching effects and mechanism of chewing gum containing various components such as ACP, HA, and TSP using various methods of experiment and analysis.
Aged
;
Calcium
;
Calcium Phosphates
;
Chewing Gum
;
Dental Enamel
;
Diphosphates
;
Durapatite
;
Ethics Committees, Research
;
Gingiva
;
Humans
;
Informed Consent
;
Mastication
;
Urea

Result Analysis
Print
Save
E-mail